Search filters
Filters
Clear AllPhase
-
183
-
156
-
2
-
194
-
1
-
152
-
17
-
402
Age
-
1246
-
593
Gender
-
29
-
49
-
3
-
1172
Virtual Trials
-
1247
-
6
New Trials
-
4
-
1249
Found 1253 All Conditions trials
A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
NIH RECOVER: Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults
This study seeks to understand why some people who got COVID-19 are still sick many months after being infected, and how this affects the body. Being sick for a long time is sometimes called “Long COVID” or “PASC”, which stands for post-acute sequelae of SARS-CoV-2 infection. Through this study, we …
Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
Participants invited to participate in a research study must have diagnosis of multiple myeloma and have been previously treated with the study drug, cilta-cel. The purpose of this research is to monitor the health status of subjects who were previously enrolled in cilta-cel.
Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations.
Study of drug PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure
The research study is being conducted to test the study drug PB2452 to see if it is safe and will reverse the bleeding effects of Brilinta® (also known as ticagrelor). Candidates must be taking Brilinta® (ticagrelor) or show intake within the past 3 days. They will be considered for participation …
UPCC 04122 A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
UPCC 11522 A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma
This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
EA5163/S1709 INSIGNA: A Randomized Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNaturedriven Analysis
This study is being done to answer the following questions: Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer? Does additional treatment …
App for Strengthening Services In Specialized Therapeutic Support
Through this project, the research team will test an app developed for tracking data collection with 30 support staff from three agencies. After observing and interviewing support staff and their supervisors, we created two different mobile apps for support staff to use that we think can be helpful when they …
UPCC 01622 Neoadjuvant PD-1 blockade in resectable Merkel cell carcinoma
Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please reer to Protocol Section 3.2 (Secondary Objective(s), Hypothesis(es), and Endpoint(s)
UPCC 09922 A Phase 1 Open-label Multicenter Dose-ranging Study to Investigate Safety and Tolerability Efficacy Pharmacokinetics Pharmacodynamics and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Please choose between Voice or SMS based delivery of verification code
or